Longeveron (NASDAQ:LGVN) Releases Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Longeveron (NASDAQ:LGVN) released its quarterly earnings data on Thursday. The company reported ($1.91) EPS for the quarter, missing the consensus estimate of ($1.70) by ($0.21), FiscalAI reports. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.80 million. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%.

Longeveron Price Performance

LGVN stock traded down $0.33 during midday trading on Thursday, hitting $2.97. The stock had a trading volume of 78,927 shares, compared to its average volume of 207,199. The business has a 50-day moving average of $3.08 and a two-hundred day moving average of $6.47. The firm has a market cap of $9.47 million, a price-to-earnings ratio of -0.30 and a beta of -0.09. Longeveron has a 52-week low of $1.31 and a 52-week high of $12.30.

Wall Street Analysts Forecast Growth

LGVN has been the subject of several recent analyst reports. Wall Street Zen raised shares of Longeveron from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $80.00.

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.